Adjuvant Activity of Monophosphoryl Lipid A for Nasal and Oral Immunization with Soluble or Liposome-Associated Antigen

Childers, Noel K.; Miller, Keri L.; Tong, Giang; Llarena, Juan Carlos; Greenway, Terrence E.; Ulrich, J. Terry; Michalek, Suzanne M.

doi:10.1128/iai.68.10.5509-5516.2000

Cited by 100 publications

(53 citation statements)

References 60 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…41,[47][48][49] Few studies have directly compared the profile of serum Ab responses after oral and nasal sensitization to the same antigen/allergen. Our finding that oral delivery of PPE and CT promotes higher levels of peanut-specific IgE responses than nasal delivery is consistent with earlier reports suggesting that Peyer's patches of the GI tract are preferred sites of IgE Ab responses.…”

Section: Discussionmentioning

confidence: 99%

Oral and Nasal Sensitization Promote Distinct Immune Responses and Lung Reactivity in a Mouse Model of Peanut Allergy

Fischer

McGhee

et al. 2005

The American Journal of Pathology

View full text Add to dashboard Cite

Despite structural and functional differences between the initial sites of contact with allergens in the gastrointestinal and nasal tracts, few animal models have examined the influence of the mucosal routes of sensitization on host reactivity to food or environmental antigens. We compared the oral and nasal routes of peanut sensitization for the development of a mouse model of allergy. Mice were sensitized by administration of peanut proteins in the presence of cholera toxin as adjuvant. Antibody and cytokine responses were characterized, as well as airway reactivity to nasal challenge with peanut or unrelated antigens. Oral sensitization promoted higher levels of IgE, but lower IgG responses, than nasal sensitization. Both orally and nasally sensitized mice experienced airway hyperreactivity on nasal peanut challenge. The peanut challenge also induced lung eosinophilia and type 2 helper T-cell-type cytokines in orally sensitized mice. In contrast, peanut challenge in nasally sensitized mice promoted neutrophilia and higher levels of The prevalence of peanut allergy has doubled in the last decade, and it now affects more than 3 million individuals in the United States.

show abstract

Section: Discussionmentioning

confidence: 99%

Oral and Nasal Sensitization Promote Distinct Immune Responses and Lung Reactivity in a Mouse Model of Peanut Allergy

Fischer

McGhee

et al. 2005

The American Journal of Pathology

View full text Add to dashboard Cite

show abstract

“…Montanide ISA720, a metabolizable oil adjuvant (Seppic Inc. Fairfield, NJ) [29]; MF59, squalene/oil emulsion (Chiron Corp. Emeryville, CA) [30]; QS21, a saponin derivative (Antigenics Inc. Lexington, MA) [31]; MPL (from E. coli F583 Rd mutant, Sigma-Aldrich, St Louis, MO); MPL-AF, monophosphoryl lipid A in aqueous formulation (Corixa Inc. Seattle, WA) [32]; MPL-SE, monophosphoryl lipid A in squalene emulsion (Corixa Inc. Seattle WA) [33]; and Freund's Adjuvants, CFA/IFA (Gibco, Grand Island, NY). Additional formulations comprised of combinations of above adjuvants were also used, ISA720/MPL, ISA720/QS21, ISA720/QS21/MPL.…”

Section: Adjuvant Formulationsmentioning

confidence: 99%

Interleukin-6 has differential influence on the ability of adjuvant formulations to potentiate antibody reponses to a Plasmodium falciparum blood-stage vaccine

Hui

Hashimoto

2007

Vaccine

View full text Add to dashboard Cite

The efficacy of vaccine adjuvants can be influenced by the immunological environment of the host, depending on the mechanism(s) by which they exert their immunopotentiating activities. Interleukin-6 is a pleiotropic cytokine that has a broad range of biological activities on immune and non-immune cells. We investigated the role of IL-6 on the ability of nine adjuvant formulations to induce antibody responses to the P. falciparum MSP1-19 malaria vaccine, using IL-6 -/-(KO) mice. Results showed that some adjuvants, ie. MPL-SE, CFA/IFA, ISA720/QS21/MPL, depended on IL-6 for their efficacy, while others exhibited increased potency in its absence. The efficacy of adjuvants in the IL-6 KO environment cannot be solely attributed to their ability to stimulate antigen-specific cellular responses, suggesting that other biological activities of IL-6 are also important. The results further suggest that two adjuvants utilized dissimilar pathways to potentiate the same type of immune response.

show abstract

“…Liposomal protein vaccines alone have demonstrated only weak to moderate immune stimulating effect (55,56). The contribution of the liposome element of the booster immunization to immunogenicity in the heterologous immunization protocol was evaluated in two independent experiments (Table I).…”

Section: The Adjuvant Role Of Liposomes In the Heterologous Immunizatmentioning

confidence: 99%

A DNA Vaccine Prime Followed by a Liposome-Encapsulated Protein Boost Confers Enhanced Mucosal Immune Responses and Protection

Yang¹,

Whalen²,

Tirabassi

et al. 2008

The Journal of Immunology

View full text Add to dashboard Cite

A variety of DNA vaccine prime and recombinant viral boost immunization strategies have been developed to enhance immune responses in humans, but inherent limitations to these strategies exist. There is still an overwhelming need to develop safe and effective approaches that raise broad humoral and T cell-mediated immune responses systemically and on mucosal surfaces. We have developed a novel mucosal immunization regimen that precludes the use of viral vectors yet induces potent T cell responses. Using hepatitis B surface Ag (HBsAg), we observed that vaccination of BALB/c mice with an i.m. HBsAg-DNA vaccine prime followed by an intranasal boost with HBsAg protein encapsulated in biologically inert liposomes enhanced humoral and T cell immune responses, particularly on mucosal surfaces. Intranasal live virus challenge with a recombinant vaccinia virus expressing HBsAg revealed a correlation between T cell immune responses and protection of immunized mice. A shortened immunization protocol was developed that was successful in both adult and neonatal mice. These results support the conclusion that this new approach is capable of generating a Th-type-1-biased, broad spectrum immune response, specifically at mucosal surfaces. The success of this design may provide a safe and effective vaccination alternative for human use.

show abstract

Adjuvant Activity of Monophosphoryl Lipid A for Nasal and Oral Immunization with Soluble or Liposome-Associated Antigen

Cited by 100 publications

References 60 publications

Oral and Nasal Sensitization Promote Distinct Immune Responses and Lung Reactivity in a Mouse Model of Peanut Allergy

Oral and Nasal Sensitization Promote Distinct Immune Responses and Lung Reactivity in a Mouse Model of Peanut Allergy

Interleukin-6 has differential influence on the ability of adjuvant formulations to potentiate antibody reponses to a Plasmodium falciparum blood-stage vaccine

A DNA Vaccine Prime Followed by a Liposome-Encapsulated Protein Boost Confers Enhanced Mucosal Immune Responses and Protection

Contact Info

Product

Resources

About